RIGI and cancer: In this scenario, the stimulation of RIG-I, as well as the design of MEX3A inhibitors or small molecules able to counteract the binding between MEX3A and RIG-I might represent a novel strategy for cancer immunotherapy, by improving the dual function of RIG-I as cell death inducer and immune response activator (Figure 7).